Drug Profile
NVB 302
Alternative Names: NVB302Latest Information Update: 01 Feb 2018
Price :
$50
*
At a glance
- Originator Novacta Biosystems
- Developer Novacta
- Class Antibacterials; Bacteriocins; Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 01 Feb 2018 Discontinued - Phase-I for Clostridium difficile infections (In volunteers) in United Kingdom (PO)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Clostridium difficile infections(In volunteers) in United Kingdom (PO)
- 22 Jan 2016 NVB 302 is still in phase I development for Clostridium difficile infections in United Kingdom